Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

Ann Oncol. 2022 Nov;33(11):1207-1208. doi: 10.1016/j.annonc.2022.07.012. Epub 2022 Aug 1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine
  • Humans
  • Neoplasms* / drug therapy
  • Vaccines*

Substances

  • BNT162 Vaccine
  • Vaccines